Compare Barclays PLC (BCS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs ResMed Inc. — how do they compare? Barclays PLC trades at $27.98 (market cap $92.56B), while ResMed Inc. trades at $193 (market cap $28.00B). The key difference: Barclays PLC is far larger — about 3.3× ResMed Inc.'s market cap, and Barclays PLC pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| BCS | RMD | |
|---|---|---|
Market Cap | $92.56B | $28.00B |
Sector | Financials | Health |
52-Week High | $28.41 | $293.73 |
52-Week Low | $18.48 | $182.82 |
Dividend Yield | 1.67% | 1.24% |
Enterprise Value | — | $27.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $27.29, down 0.69% on the day, near its 52-week high of $28.43. The stock shows strong fundamental momentum with revenue rising to $29.14B in 2025 and net income reaching $7.17B, supported by three consecutive quarterly EPS beats. Technical indicators signal a bullish trend, while analyst sentiment remains positive with 68% buy ratings. Recent news highlights ongoing legal investigations but also underscores the bank's role in market analysis and product innovation.
The outlook for BCS is cautiously optimistic, driven by solid earnings growth and attractive valuation metrics like a P/E of 11.91 and P/B of 0.91. Key risks include potential legal liabilities from securities investigations and macroeconomic sensitivity. Investors should weigh the strong analyst support against these headwinds for balanced decision-making.
ResMed (RMD) trades at $198.50, down 2.63% on the day, with technical indicators showing a bearish trend near support at $197. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $2.86 versus $2.80 expected, and robust profitability with a 27.44% net margin. Recent strategic moves include the sale of its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets.
The outlook remains positive given analyst consensus targets near $249.57, representing significant upside, though near-term technical weakness and competitive pressures in digital health pose risks. Revenue growth is projected to reach $5.5 billion in 2026, supporting a solid investment case for long-term holders despite current bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
